Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B

Liver Int. 2018 Feb:38 Suppl 1:84-89. doi: 10.1111/liv.13641.

Abstract

Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first-line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long-term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.

Keywords: chronic hepatitis B; efficacy; entecavir; safety; tenofovir alafenamide; tenofovir disoproxil fumarate; treatment.

Publication types

  • Review

MeSH terms

  • Adenine / analogs & derivatives
  • Administration, Oral
  • Alanine
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Guanine / analogs & derivatives
  • Hepatitis B, Chronic / drug therapy*
  • Humans
  • Nucleosides / adverse effects
  • Nucleosides / analogs & derivatives
  • Nucleosides / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Tenofovir
  • Time Factors
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Nucleosides
  • entecavir
  • Guanine
  • Tenofovir
  • tenofovir alafenamide
  • Adenine
  • Alanine